HLS Partners With Bayer to Sell Heart Failure Medication in Canada

11:10 AM EST, 11/03/2026 (MT Newswires) -- HLS Therapeutics (HLS.TO) said on Tuesday that it is partnering with Bayer to commercialize Verquvo (vericiguat) in Canada. Verquvo is indicated for the treatment of symptomatic chronic heart failure in certain adult patients. HLS will be responsible for commercial and medical education activities, and recording Verquvo net sales from the first quarter of 2027. The company will pay royalties on net sales to Bayer, along with potential additional payments tied to commercial milestones. Bayer will hold market authorization for Verquvo, and retain responsibility for regulatory, pharmacovigilance, pricing and reimbursement matters, a statement added. HLS shares were last seen down CA$0.02 at CA$4.45 per share on the Toronto Stock Exchange. Price: 4.45, Change: -0.02, Percent Change: -0.45